GlassScriptPhysician profile
Michael J Brennan
NPI 1538117049
$19,025.72
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $4,478 · 2021: $10K · 2022: $1,841 · 2023: $1,441 · 2024: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $740.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $4,587.72 | 2019-2021 | |
| Redhill Biopharma INC. | $4,295.30 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $3,791.69 | 2019-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,133.91 | 2019-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $1,083.62 | 2019-2024 | Xtampza |
| Purdue Pharma L.P. | $1,000.00 | 2020 | |
| Abbvie INC. | $604.35 | 2021-2023 | Qulipta, Ubrelvy |
| Pfizer INC. | $324.46 | 2019-2024 | |
| Upsher-Smith Laboratories LLC | $264.19 | 2020-2023 | |
| Zyla Life Sciences, INC. | $204.01 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $174.43 | 2019-2021 | |
| Allergan, INC. | $163.02 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $162.96 | 2021 | |
| Lilly USA, LLC | $162.23 | 2019-2022 | |
| Amgen INC. | $146.96 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $135.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $133.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $111.73 | 2021-2023 | Ajovy |
| Ibsa Pharma INC. | $72.87 | 2020-2021 | |
| Sentynl Therapeutics, INC. | $62.86 | 2019 | |
| Horizon Therapeutics Plc | $49.31 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $43.01 | 2021-2022 | |
| Lundbeck LLC | $42.31 | 2020-2022 | |
| Protega Pharmaceutials INC | $41.08 | 2023 | Roxybond |
| Hikma Pharmaceuticals USA | $33.58 | 2021 | |
| Shionogi INC | $29.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $28.84 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.81 | 2019 | |
| Kaleo, INC. | $18.08 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.87 | 2019 | |
| Daiichi Sankyo INC. | $17.62 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.71 | 2023 | Seglentis |
| Bioventus LLC | $14.39 | 2019 | |
| Nevro Corp. | $11.85 | 2021 | |
| Uswm, LLC | $11.04 | 2021 | |
| Mdd US Operations, LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.